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Abstract Here, we present results for DPA1 and DPB1
four-digit allele-level typing in a large (n05,944) sample
of unrelated European American stem cell donors previous-
ly characterized for other class I and class II loci. Examina-
tion of genetic data for both chains of the DP heterodimer in
the largest cohort to date, at the amino acid epitope, allele,
genotype, and haplotype level, allows new insights into the
functional units of selection and association for the DP
heterodimer. The data in this study suggest that for the
DPA1-DPB1 heterodimer, the unit of selection is the com-
bined amino acid epitope contributed by both the DPA1 and
DPB1 genes, rather than the allele, and that patterns of LD
are driven primarily by dimer stability and conformation of
the P1 pocket. This may help explain the differential pattern
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of allele frequency distribution observed for this locus rela-
tive to the other class II loci. These findings further support
the notion that allele-level associations in disease and trans-
plantation may not be the most important unit of analysis,
and that they should be considered instead in the molecular
context.
Keywords DPA1 . DPB1 . Heterodimer . Haplotype . Amino
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Introduction
The human leukocyte antigen (HLA) complex on chromo-
some 6 is the most polymorphic region of the human genome,
and while doubly polymorphic heterodimeric molecules are
relatively rare in human biology, this is a defining feature of
the HLA class II gene products. Within the class II region, the
DRB1 locus is recognized as significantly more polymorphic
relative to the other beta chain genes, with >1,000 alleles
recognized to date, and is nearly 150-fold more diverse than
the DRA locus, where only seven alleles have been identified
(http://www.ebi.ac.uk/imgt/hla/stats.html). In contrast, the
HLA-DQ and HLA-DP systems are characterized by having
more moderate variation overall relative to HLA-DR, but
more diversity in genes for the alpha chains, resulting in less
imbalance between levels of alpha and beta diversity; the ratio
of beta/alpha known alleles is approximately 4:1 for these
genes. In the DQ system, alpha chain diversity, coupled with
relatively even allele frequency distributions for both DQA1
and DQB1 in most human populations (Fernandez-Vina et al.
1991; Solberg et al. 2008; Begovich et al. 1992; Slatkin 2000),
potentially increases polymorphism at the heterodimer level.
At the same time, the DQ system is characterized by near
complete linkage disequilibrium (LD), and evidence suggests
that the LD is driven in part by structurally permissive and
nonpermissive pairings of the alpha and beta chains, which
may restrict overall heterodimer polymorphism. Much previ-
ous work (Begovich et al. 1992; Bugawan et al. 2000;
Fernandez-Vina et al. 1991; Hollenbach et al. 2001; Klitz et
al. 2003) has demonstrated that certain combinations ofDQA1
and DQB1 alleles are almost never seen on the same haplo-
type, and there is evidence to suggest that these pairings do not
produce stable cell surface heterodimers (Kwok et al. 1993;
Kwok and Nepom 1989). In contrast to the balanced poly-
morphism observed for DQA1 and DQB1, only a few alleles
predominate in most human populations for both DPA1
and DPB1 (Gendzekhadze et al. 2004; Steiner et al. 2000)
(Begovich et al. 2001; Pérez-Miranda et al. 2004; Solberg
et al. 2008), resulting in significantly less potential heterodi-
meric diversity within a given population. However, while
much is known about alpha–beta haplotypic associations in
the HLA-DQ system, becauseDPA1 genotyping is infrequently
performed, there have been only limited studies with
relatively small sample sizes describing DPA1∼DPB1 haplo-
types (Begovich et al. 2001; Gendzekhadze et al. 2004).
Evidence for lower levels of cell surface expression of
the DP molecule relative to other classical HLA molecules
(Edwards et al. 1986; Guardiola and Maffei 1993) has
historically led to the notion that DP may be less important
than other HLA in human health. Furthermore, a lack of
evidence for balancing selection, a hallmark of the other
class II loci, has been interpreted as an indication that DP
may not play an important role in protection from patho-
gens in humans. In both solid organ and hematopoietic
stem cell transplantation (HSCT), standard protocols do
not call for matching at DP, and DP typing is not routinely
performed. However, recent data suggest that DP match
status may play an important role in HSCT outcome
(Crocchiolo et al. 2009; Fleischhauer et al. 2006; Gallardo
et al. 2004; Shaw et al. 2003, 2006; Vrana et al. 2006; Zino
et al. 2004, 2007; Fleischhauer et al. 2012), although the
nature and direction of the impact are still the subject of
debate. DP molecules can serve as targets of alloreactivity
with clinical consequences in HSCT, demonstrated by data
showing association of HLA-DP mismatching with re-
lapse, GvHD, rejection and nonrelapse mortality after un-
related HSCT, as well as data suggesting that anti-DP
donor-specific antibodies increase the risk of graft failure
(Ciurea et al. 2011; Crocchiolo et al. 2009; Fleischhauer et
al. 2006; Petersdorf et al. 2001; Shaw et al. 2007;
Spellman et al. 2010; Zino et al. 2004; Fleischhauer et al.
2012). Likewise, anti-DP antibodies appear to play an
important role in kidney transplant outcomes (Singh et al.
2010; Thaunat et al. 2009). In addition, numerous studies
suggest that DPB1 is associated with predisposition to
infectious disease such as hepatitis B (Howell and Visvanathan
2009; Kamatani et al. 2009), autoimmune disorders such as
multiple sclerosis (Begovich et al. 1990; Odum et al. 1988) and
juvenile idiopathic arthritis (Hollenbach et al. 2010), and leu-
kemia (Taylor et al. 2002). The very strong evidence for a role
of DPB1 in development of chronic beryllium disease (CBD;
Amicosante et al. 2001; Fontenot et al. 2000; Lombardi et al.
2001) suggests that despite low levels of cell surface expres-
sion, antigen presentation by the DP molecule is capable of
stimulating a robust and clinically significant immune
response.
Here, we present results for DPA1 and DPB1 four-digit
allele-level typing in a large (n05,944) sample of unrelated
European American stem cell donors previously character-
ized for other class I and class II loci (Maiers et al. 2007).
Examination of genetic data for both chains of the DP
heterodimer in the largest cohort to date, at the amino acid
epitope, allele, genotype, and haplotype level, allows new
insights into the functional units of selection and association
for the DP heterodimer.
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Methods
Subjects
The study cohort consisted of 5,944 (self-identified) European
Caucasian individuals who donated hematopoietic stem cells
for unrelated transplants facilitated by the National Marrow
Donor Program (NMDP) during the years 1988 to 2003.
Primary granulocyte and mononuclear cell preparations and
transformed B cell lines from donors were distributed from the
NMDP Research Sample Repository (Blood Systems Re-
search Institute, San Francisco, CA) to nine laboratories for
DNA preparation and HLA genotyping.
Genotyping
Samples were genotyped at allele level for DPA1 and DPB1
(results from this same cohort for other loci: HLA-A, HLA-B,
HLA-C,HLA-DRB1, andHLA-DQB1were reported previous-
ly; Klitz et al. 2003; Maiers et al. 2007). Sequence-specific
oligonucleotide typing assays were performed as previously
described (Williams et al. 2008) using reagents from the local
laboratory, the 11th and 12th international workshops (Bignon
and Fernandez-Vina 1997), and commercial vendors (Steiner
et al. 2000). Sequence-based typing for DPA1 was based on a
1,366-nucleotide PCR product including exons 2 through 4 as
described previously (Rozemuller et al. 1995). DPB1 generic
sequencing was based on a 574-nucleotide PCR product in-
cluding exon 2 prepared from genomic DNA (Versluis et al.
1993) with heterozygous ambiguity resolved by allele-
specific amplification or PCR-SSP.
The 5,944 samples were genotyped by nine different labo-
ratories between 1994 and 2004. In order to maintain consis-
tent reporting during the course of this project, results were
interpreted to only considerDPA1 andDPB1 alleles identified
in the 1994 HLA Nomenclature Report (Bodmer et al. 1994).
One thousand six hundred seventy-one (28.1 %) individuals
(3,342 chromosomes) were genotyped by two different labo-
ratories for quality control; the remaining 4,273 (71.9 %)
individuals were genotyped by a single laboratory.
Resolution of discrepant results and ambiguous genotypes
The results were transferred from the nine laboratories via
electronic files to the NMDP data center for interlaboratory
comparison and also comparison with any typing previously
reported by the transplant center (when available). Sixty-
eight individuals (1.1 %) had previously reported results for
DPB1, and two (0.03 %) had previously reported results for
DPA1. A total of 20 out of 3,342 (0.6 %) discrepancies for
DPB1 and 9 out of 3,342 (0.26 %) for DPA1 were identified
and subsequently resolved. Etiology and resolution of dis-
crepancies for this cohort generally followed the categories
reported for a largely overlapping subset of N02,578 donors
(Williams et al. 2008).
Definition of serological and immunogenic epitopes
of DPB1
Cano and Fernandez-Vina (2009) described two sets dimorphic
amino acid epitopes at positions 56 and 85–87 that together
accounted for themajority of DP serological reactivity observed
in a sample of solid organ transplant patients. The first sequence
dimorphism is found at DPB1 amino acid position 56, with
either Ala (A) or Glu (E) at this site. The second variable region
corresponds to amino acid positions 85–87 in the hypervariable
region (HVR) “F,” and these amino acids are in complete LD;
most DPB1 alleles will have either the EAV (Glu-Ala-Val) or
GPM (Gly-Pro-Met) motif in these positions. Combined, these
two sequence dimorphisms were found to yield four serological
specificities, defined as DP1 (56A; 85–87 EAV), DP2 (56E;
85–75 GPM), DP3 (56E; 85–87 EAV), and DP4 (56A; 85–87
GPM). In addition to standard analysis at theDPB1 allele level,
analysis was performed individually for these amino acid
motifs, as well as for the four serological epitopes.
An alternative epitope, recognized by T cells, was defined
in Zino et al. (2004, 2007) and Fleischhauer et al. (2012) on
the basis of alloreactive T cell cross-reactivity patterns and is
therefore referred to as T cell epitope (TCE). The TCE has so
far not been mapped to defined structural amino acid residues,
but was surmised to impact T cell alloreactivity via variable
peptide presentation and shown to determine clinically non-
permissive mismatches for DPB1 in unrelated HSCT (Zino et
al. 2004, 2007). The TCE is shared by defined subsets of DPB1
alleles, and allows alleles at this locus to be assigned to three
categories of immunogenicity (highly immunogenic group 1
including DPB1*09:01, 10:01, 17:01; intermediately immuno-
genic group 2 including DPB1*03:01, 14:01, 45:01, 86:01,
104:01; and poorly immunogenic group 3 including most other
alleles; Supplemental Table 2). In the present study, DPB1
alleles were categorized according to the TCE model outlined
in Zino et al. (2004, 2007) and analyzed on that basis.




The amino acid residue
at position 31 is given
for each allele










Immunogenetics (2012) 64:559–569 561
Statistical analysis and data visualization
Hardy–Weinberg equilibrium
Fit of the data to Hardy–Weinberg expectations was assessed
using both an exact test (Guo and Thompson 1992) and a
standard goodness-of-fit (chi-squared) test implemented in the
PyPop software package (Lancaster et al. 2003).
Homozygosity statistic
The homozygosity F statistics of Watterson (1978), calcu-
lated as the expected proportion of homozygotes under
Hardy–Weinberg, was used as a measure of the allele and
Table 2 Frequencies of DPB1
alleles
Amino acid motifs for positions
56 and 85–87 are given for each
allele. The serological epitope
DP1–DP4 described in Cano and
Fernandez-Vina (2009) is given
along with the T cell receptor
group defined in Zino et al.
(2004)
NC not classified
DPB1 Frequency Position 56 Positions 85–87 Serological epitope TCE group
04:01 0.4385 A GPM 4 3
02:01 0.1274 E GPM 2 3
04:02 0.1152 E GPM 2 3
03:01 0.1011 E EAV 3 2
01:01 0.0506 A EAV 1 3
11:01 0.0229 A EAV 1 3
05:01 0.0205 A EAV 1 3
06:01 0.0183 E EAV 3 3
10:01 0.0166 E EAV 3 1
13:01 0.0157 A EAV 1 3
17:01 0.0150 E EAV 3 1
14:01 0.0117 E EAV 3 2
19:01 0.0072 A EAV 1 3
09:01 0.0072 E EAV 3 1
15:01 0.0071 A GPM 4 3
02:02 0.0067 A GPM 4 3
20:01 0.0057 E EAV 3 3
23:01 0.0054 A GPM 4 3
16:01 0.0052 E EAV 3 3
34:01 0.0006 A GPM 4 3
35:01 0.0003 E EAV 3 NC
45:01 0.0003 E EAV 3 2
33:01 0.0002 A GPM 4 3
39:01 0.0002 A GPM 4 3
26:01 0.0001 A EAV 1 NC
30:01 0.0001 A EAV 1 NC
36:01 0.0001 A EAV 1 NC
54:01 0.0001 A EAV 1 NC
87:01 0.0001 A EAV 1 NC
18:01 0.0001 E GPM 2 NC
51:01 0.0001 E GPM 2 3
72:01 0.0001 A GPM 4 3
99:01 0.0001 A GPM 4 3
Table 3 Frequency of
polymorphic amino
acids at DPB1 positions
56 and 85–87














DP1 A EAV 0.117
DP2 E GPM 0.243
DP3 E EAV 0.181
DP4 A GPM 0.459
562 Immunogenetics (2012) 64:559–569
amino acid epitope frequency distributions and compared to




where pi is the frequency of the ith allele at a locus. The test
is based on the observed number of alleles (k) at a locus and
sample size (2n). The homozygosity test was applied using
the exact test described by Slatkin (1994) and implemented
in the PyPop software package (Lancaster et al. 2003).
Haplotype and disequilibrium estimation
Haplotype estimation was accomplished using an expecta-
tion–maximization algorithm which assigns population-level
haplotype frequencies using simultaneous maximum likeli-
hood estimation of n locus haplotype frequencies. Haplotypes
were estimated for DPA1 and DPB1 alleles, as well as for
DPA1 alleles and DPB1 amino acid and T cell epitopes.
A pairwise linkage disequilibrium statistic was calculated
for each allele∼allele or allele∼epitope haplotype:
Dij ¼ xij  piqj;
where xij is the estimated haplotype frequency and pi and qj
are the ith and jth allele frequencies at the two loci. To
account for differing allele or epitope frequencies at the loci,
a normalized disequilibrium value was used:
Dij ¼ Dij=Dmax;
where Dmax is the lesser of piqj and (1−pi)(1−qj), when Dij
is <0 and pi(1−qj) and qj(1−pi), when Dij is >0.
A global disequilibrium statistic was also used to sum-
marize disequilibrium at all possible haplotypes for two loci






where pi and qj are the observed allele frequencies at each of
the two loci having k and l alleles, respectively. A normal-
ized W was calculated to address differing numbers of
alleles at the different loci:
Wn ¼ W= min k;lð Þ  1ð Þ1=2;
where k and l are the number of alleles at two loci (Cohen et
al. 1988). The values of Wn fall between 0 and 1, and is
identical to Cramer’s V (Cramer 1946).
Haplotype estimation was accomplished using the “hap-
lo.em” function in the “haplo.stats” package (Sinnwell and
Schaid 2009) for the R language for statistical computing (R
Core Development Team 2009), version 2.9.2. All LD val-
ues were computed using the “ldkl” function in the “gap”
package (Zhao and Tan 2009) for R. Clustered heatmaps of
LD values were accomplished using the “heatmap” function
in the base “stats” package for R, which utilizes a hierarchi-
cal similarity clustering procedure.
The DP heterodimer was visualized using Polyview 3D
(Porollo and Meller 2007; http://polyview.cchmc.org/
polyview3d.html) and input coordinates of the HLA-DP2
structure from Dai et al. (2010) in the Protein Data Bank
(www.pdb.org; PDB ID code 3LQZ).
Results
DPA1 and DPB1 allele frequency distributions
Genotypic distributions for both DPA1 and DPB1 do not
differ significantly from expectations under Hardy–Wein-
berg equilibrium. Allele frequencies for DPA1 are given in
Table 1. In this population, two of the nine DPA1 alleles
observed in the study cohort account for >95 % of the
variation at this locus, with DPA1*01:03 f00.819 and
DPA1*02:01 f00.140. Of the remaining alleles, only
DPA1*02:02 is detected at a frequency greater than 1 %,
and three of the nine alleles observed are found only once
among the 11,888 chromosomes sampled here.
As expected, more diversity is observed for DPB1
(Table 2), where 33 distinct DPB1 alleles are seen in
this cohort, but a single allele predominates and a
handful of other alleles are present at moderate frequen-
cies. Observations are consistent with those in numerous
other European Caucasian populations, where DPB1*04:01
is the single most common allele (f00.439). Three remaining
Table 5 Frequency of TCE groups (Zino et al. 2004) and amino acid
positions 85–87 motifs within each group





Not classified 0.0008 0.889
Table 6 Homozygosity statistic (F) for DPA1, DPB1, and DPB1
defined in terms of serological epitopes (Cano and Fernandez-Vina
2009) or T cell epitopes (TCE; Zino et al. 2004)
Locus/epitope group F (obs) F (exp) p
DPA1 0.691 0.517 0.798
DPB1 0.237 0.195 0.784
DPB1 serological groups P1–P4 0.316 0.748 0.0035
DPB1 TCE groups 1–3 0.734 0.817 0.318
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alleles (DPB1*02:01, DPB1*04:02, and DPB1*03:01) are
seen at frequencies >10 %, while eight more alleles
(DPB1*01:01, DPB1*11:01, DPB1*05:01, DPB1*06:01,
DPB1*10:01, DPB1*13:01, DPB1*17:01, and DPB1*14:01,
in order of decreasing frequency) have frequencies >1 %.
Similar to the results for DPA1, a little less than one third
(9 of 33) of the alleles are observed only as singleton
copies.
DPB1 serological epitopes
The frequencies in the study population of the amino acid
epitopes at positions 56 and positions 85–87 are shown in
Table 3. Position 56 is marked by extremely balanced fre-
quencies of 0.576 for alanine at this position and 0.424 for
glutamic acid. The amino acids within the second motif ex-
amined here, at positions 85–87 in the HVR “F,” are in
complete LD, with one of two epitopes in all DPB1 alleles
in this sample: either EAV (f00.30) or GPM (f00.70). To-
gether, these two sequence dimorphisms correspond to four
serological specificities: DP1, DP2, DP3, and DP4; the fre-
quencies of these are given in Table 4.
DPB1 TCE
When the data for this cohort are examined with respect to
the TCE immunogenicity groups defined by Zino et al.
(2004, 2007), it is apparent that the immunogenic TCE
group 1 and 2 alleles together account for only 15.2 % of
observed alleles (Table 5). TCE group 1 alleles all bear the
“EAV” motif in positions 85–87, and are all in LD with
DPA1*02:01. However, neither the 85–87 EAV nor the
presence of DPA1*02:01 was specific for alleles from TCE
group 1 as both are found also in some alleles from TCE
groups 2 and 3 (Table 5 and Supplemental Table 2).
Homozygosity statistic
Calculation of Watterson’s homozygosity statistic (F) for
both DPA1 and DPB1 reveals that the allele frequency
distributions for both loci do not differ significantly
from expectations under a neutral model (Table 6). In
contrast, when the frequency distributions for DPB1 are
analyzed with respect to the four serological specific-
ities, DP1–DP4 (Cano and Fernandez-Vina 2009) are
significantly more even than expected under neutrality
(p<0.005), suggesting evidence for balancing selection
for these specificities (Table 6). The frequency distribu-
tions of DPB1 alleles in the three TCE groups, on the
other hand, do not depart significantly from neutral
expectations.
DPA1∼DPB1 haplotypic associations and linkage
disequilibrium
Population-level estimates for all possible DPA1-DPB1 hap-
lotypes are given in Supplemental Table 1. Three haplo-
t y p e s , DPA1 * 01 : 0 3∼DPB1* 0 2 : 0 1 ( f 00 . 1 2 4 ) ,
DPA 1 * 0 1 : 0 3 ∼DP B 1 * 0 4 : 0 1 ( f 00 . 4 3 3 ) , a n d
DPA1*01:03∼DPB1*04:02 (f00.114) account for more than
two thirds of the observed haplotypes in this cohort. Table 7
shows the 15 most frequent haplotypes with a cumulative
frequency of >95%. The normalized LD (D′) statistics for these
haplotypes show extensive LD between DPA1 and DPB1
alleles; the notable exception is DPA1*02:02∼DPB1*01:01,
Table 7 Frequency and linkage
disequilibrium of the 15 most
common DPA1∼DPB1
haplotypes
The amino acid motifs at DPA1







DPA1*01:03~DPB1*04:01 M GPM 5,146.34 0.4329 0.9295
DPA1*01:03~DPB1*02:01 M GPM 1,470.19 0.12367 0.8404
DPA1*01:03~DPB1*04:02 M GPM 1,350.52 0.1136 0.9216
DPA1*01:03~DPB1*03:01 M EAV 1,189.94 0.1001 0.9447
DPA1*02:01~DPB1*01:01 Q EAV 506.21 0.04258 0.8165
DPA1*02:01~DPB1*11:01 Q EAV 268.98 0.02263 0.9871
DPA1*01:03~DPB1*06:01 M EAV 216 0.01817 0.9746
DPA1*02:01~DPB1*10:01 Q EAV 191.97 0.01615 0.9703
DPA1*02:02~DPB1*05:01 Q EAV 180.66 0.0152 0.7312
DPA1*02:01~DPB1*17:01 Q EAV 173.97 0.01463 0.9737
DPA1*02:01~DPB1*13:01 Q EAV 162.04 0.01363 0.8502
DPA1*02:01~DPB1*14:01 Q EAV 137.99 0.01161 0.9916
DPA1*02:02~DPB1*01:01 Q EAV 86.49 0.00728 0.17
DPA1*02:01~DPB1*09:01 Q EAV 85 0.00715 1
DPA1*02:02~DPB1*19:01 Q EAV 82.99 0.00698 0.9755
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which is observed in this cohort at a frequency of less than 1 %.
The overall (global) linkage disequilibrium (Wn)00.515 for
DPA1∼DPB1 associations.
When DPA1-DPB1 haplotypes are examined with respect
to DPB1 amino acid motifs, rather than alleles, the patterns
of association suggest that the DPA1 allele that is associated
with DPB1 is strictly related to DPB1 polymorphisms at
amino acid positions 85–87 in the HVR “F.” Near complete
LD (D′00.94, p<0.05) is observed between DPA1*0201
and DPB1 alleles with the EAV motif, while DPA1*0103
nearly always occurs on a haplotype with the DPB1 85–87
GPM motif (D′00.87, p<0.01). The global LD value (Wn)
between DPA1 and positions 85–8700.65. These relation-
ships are evident in Fig. 1, which shows a clustered heatmap
for DPA1∼DPB1 haplotype D′ values. DPB1 alleles break
down into two primary clusters, which are nearly strictly
defined by polymorphisms at positions 85–87.
These results for LD between DPA1 alleles and DPB1
amino acid motifs stand in stark contrast to the patterns of
LD observed between amino acid motifs within DPB1.
Fig. 1 A clustered heatmap for DPA1∼DPB1 haplotype normalized linkage disequilibrium values (D′). DPA1 alleles are shown along the x-axis,
and DPB1 alleles are shown on the y-axis
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Discussion
The high levels of linkage disequilibrium between DPA1
and DPB1 suggest the possibility of nonpermissive combi-
nations for the heterodimer, similar to that suggested for the
DQ molecule. It has been shown that for the heterodimer
encoded by DQA1-DQB1, certain alpha–beta combinations
are unstable at the cell surface, and these have been associ-
ated with the patterns of LD for these genes. The patterns of
LD observed here are consistent with the notion that partic-
ular combinations of DP alpha and beta chains may be
structurally impermissible. In the DP heterodimer, positions
85–87 are thought to be important primarily in interaction
with the alpha chain, as well as participating in the P1
pocket (Diaz et al. 2003). This is analogous to the more
well-characterized DRB1 protein structure: DPB1 position
84, in LD with positions 85–87, corresponds to DRB1
position 86, which is thought to contribute to both dimer
stability (Verreck et al. 1993) and the position of bound
peptide in the P1 pocket, impacting the MHC–peptide con-
formation (Wu and Gorski 1997).
While significantly less polymorphic than DRB1, the
patterns of LD and amino acid variation for the DPB1 locus
lend further support to the importance of the P1 pocket in
driving DPA1∼DPB1 LD. In contrast to DPB1, DPA1 poly-
morphism is extremely limited and restricted to only a
handful of amino acid sites. Examination of the amino acid
sequences for the DPA1 alleles reveals that a single amino
acid polymorphism at position 31 [methionine (M) or glu-
tamine (Q)] subdivides the alleles at this locus along the
lines of the patterns of LD (Table 1). Position 31, like
positions 85–87 in DPB1, participates in the P1 pocket.
Figure 2 shows the crystal structure for DP2 (Dai et al.
2010) with position 31 on DPA1 and positions 84–87 for
DPB1, and their side chains, highlighted. The structure
makes clear the critical role of these residues in the P1
pocket of the peptide-binding region, as well as interaction
between the alpha and beta chains. While beta chain posi-
tions 84–87, located within the peptide-binding region alpha
helix, is antigenic and most likely is in contact with bound
peptide and the T cell receptor, position 31 on the alpha
chain, forms part of the beta-pleated sheet that forms the
floor of the peptide-binding groove and is not exposed to the
TCR or solvent.
The critical role of position 31 in determining LD with
DPB1 alleles is illustrated by the rare DPA1*01:06:02 allele,
first characterized in an individual from Kenya (Peterson et
al. 2008). The novel allele was initially detected due to the
observation of heterozygosity at position 31 (methionine→
glutamine) for a genotyping otherwise consistent with
DPA1*01:03 homozygous. Glutamine at position 31 is one
of two amino acid positions delineating the DPA1*02:01
and 02:02 alleles, which are in near complete LD with
DPB1 alleles bearing the position 85–87 “EAV” motif.
Interestingly, the Kenyan individual in whom this allele
was identified was heterozygous at DPB1, with the “EAV”
motif present in one allele, DPB1*01:01:01, but not the
other, DPB1*02:01:02.
Fig. 2 The crystal structure for the DP2 molecule, with position 31 on
DPA1 and positions 84–87 for DPB1, and their side chains, highlighted
(position 31 (DPA1)—cyan; positions 84–87 (DPB1)—magenta)
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Here, we find that very little LD exists between the pair
of sequence dimorphisms at positions 56 and 85–87,
corresponding to the serological specificities described above,
with Wn00.242.
While the allele frequency distributions for DPA1 and
DPB1 do not differ significantly from neutral expectations,
the frequencies for the broad serological types DP1–DP4 are
significantly more even than expected under neutrality, sug-
gesting evidence for balancing selection for these specific-
ities. These findings are in keeping with those from other
studies in multiple human populations, where, unlike other
class II loci, the DPB1 locus did not show evidence for
balancing selection at the allele level. In most populations
studied to date, DPB1 frequency distributions did not differ
significantly from expectations under neutrality (Begovich
et al. 2001; Salamon et al. 1999; Solberg et al. 2008),
or showed evidence of directional, or purifying selection
(Hollenbach et al. 2001; Pérez-Miranda et al. 2004). How-
ever, when the data in Salamon et al. (1999) were examined
at the amino acid level, several amino acid sites were found
to have significantly balanced polymorphism; notably, the
most balanced sites were found to be positions 55–56 and
84–87, consistent with the findings in the present study.
Salamon et al. concluded that selection may be operating
at the amino acid level in DPB1, and that because this locus
is characterized by polymorphism primarily related to gene
conversion events, resulting in lower overall polymorphism,
this selective effect is masked at the allele level. More recent
work by Mack (2011, personal communication) has con-
firmed that positions 55–56 and 84–87 appear to be partic-
ularly balanced for DPB1 in most populations worldwide,
regardless of whether the DPB1 allele frequencies are even
or directionally skewed in the population.
Strikingly, there is more evidence of recombination be-
tween DPB1 positions 56 and 85–87 (Wn00.28), within the
gene, than between DPA1 and DPB1 positions 85–87 (Wn0
0.65), i.e., between two adjacent genes. The finding of
minimal LD between DPB1 positions 56 and 85–87 is in
keeping with numerous studies describing evidence for a
history of extensive recombination within the DPB1 locus.
While gene conversion and recombination are thought to be
an important factor in HLA polymorphism, Buhler and
Sanchez-Mazas (2011) have noted that HLA-DPB1 appears
to have been particularly impacted by gene conversion
relative to other HLA loci, and DPB1 alleles are much more
closely related to each other than alleles of other loci; the
authors concluded that the patterns of allele and amino acid
frequency distributions in world populations show evidence
of ancient, rather than recent, balancing selection.
It is interesting to note that the position 56 and 85–87
motifs appear to be characteristics of a specific DP super-
type defined by an unusually similar peptide-binding motif
(Sidney et al. 2010) and identified among most common
DPB1 alleles in most human populations. While the super-
type largely shares specificity in the main P6 pocket of the
peptide-binding region, the position 85–87 motif impacts P1
specificity. An alternative peptide-binding motif for
DPB1*09:01 (Dong et al. 1995) is markedly different from
that for the common DP supertype that includes
DPB1*02:01 and DPB1*04:01. Interestingly, DPB1*09:01
is the prototype allele of the highly immunogenic TCE
group 1 in the original paper by Zino et al. (2004). The
TCE group 1 alleles all possess the EAV motif at positions
85–87, and in this study were always observed with
DPA1*02:01, consistent with observations for all DPB1
alleles with this motif. It is tempting to speculate that the
strong alloreactivity to this TCE group demonstrated both
clinically and in mixed lymphocyte culture reactions in vitro
(Sizzano et al. 2010; Crocchiolo et al. 2009; Zino et al.
2004; Fleischhauer et al. 2012) could be correlated with
the presence of this motif in association with the DPA1
linkage. Likewise, the very strong association of DPB1 with
CBD has been pinpointed to a specific role for glutamic acid
at amino acid position 69, suggesting that for DPB1 the
amino acid residue, rather than allelic identity, may be the
important unit of association in human disease.
Taken together, the data in this study suggest that for the
DPA1-DPB1 heterodimer, the unit of selection is the
combined amino acid epitope contributed by both the
DPA1 and DPB1 genes, rather than the allele, and that
patterns of LD are driven primarily by dimer stability and
conformation of the P1 pocket. This may help explain the
differential pattern of allele frequency distribution observed
for this locus relative to the other class II loci. These find-
ings further support the notion that allele-level associations
in disease and transplantation may not be the most important
unit of analysis, and that they should be considered instead
in the molecular context.
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